Draw-10: A Weekly Blood Draw Study to Understand the Biological Variability of Plasma pTau-217

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06742944

Acronym

Draw-10

Enrollment

100

Registered

2024-12-19

Start date

2025-01-27

Completion date

2025-11-30

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

plasma pTau217

Brief summary

This is an observational study that will serially collect 10 plasma samples over the course of 9 weeks from the same individuals to assess fluctuations in blood biomarker results.

Detailed description

Blood biomarkers offer a less invasive and cheaper method for identifying Alzheimer's disease (AD)-related changes. Already, blood biomarkers for AD are being adopted by clinical practice and their use will only expand in coming years. However, blood biomarkers are susceptible to fluctuations not yet well characterized. Such fluctuations, although rarely observed in current research settings, may influence the biological evaluation of dementia once implemented into routine settings. The study at present aims to identify how blood biomarkers fluctuate over a short period of time in the same individual and assess drivers of these fluctuations.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* able and wiling to provide informed consent * Aged 50-80 years old at the time of signing study consent; participants aged 50-59 years will be no more than 20% of the total study population * Has normal cognition or mild impairment at screening MoCA by a score of greater than or equal to 18; participants with a Montreal Cognitive Assessment (MoCA Test) score between 18-25 will be no more than 20% of the total study population * able and wiling to fully comply with study procedures defined in the protocol * Written and spoken fluency in English

Exclusion criteria

* Plans to begin any new treatment or is having surgery during the 9-week draw timeframe * Currently enrolled in a clinical trial using an investigational drug

Design outcomes

Primary

Measure	Time frame	Description
Fluctuations in plasma pTau217 biomarker results	9 weeks	Assess within participant changes in plasma pTau217 biomarker assay levels over the course of the study
Frequency of large unknown biomarkers spike	9 weeks	Determine the frequency of large, unknown biomarkers spike that would influence a clinical decision.

Countries

United States

Outcome results